Evidence map›Paper›PMID 41438249›Full record

ArticleMass spectrometry (Tokyo, Japan)2025

Stepwise Monitoring of Ligand Exchange on Gold Nanorods: From Cetyltrimethylammonium Bromide to Thiol-Functionalized Biocompatible Phosphorylcholine Using Matrix-Free LDI-TOF Mass Spectrometry.

Hideya Kawasaki, Yasuhiko Iwasaki, Ryuichi Arakawa

Abstract read
In one paragraph

Article in Mass spectrometry (Tokyo, Japan), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Hideya KawasakiDepartment of Chemistry and Materials Engineering, Faculty of Chemistry, Materials and Bioengineering, Kansai University, Suita, Osaka 564-8680, Japan.
Yasuhiko IwasakiDepartment of Chemistry and Materials Engineering, Faculty of Chemistry, Materials and Bioengineering, Kansai University, Suita, Osaka 564-8680, Japan.
Ryuichi ArakawaDepartment of Chemistry and Materials Engineering, Faculty of Chemistry, Materials and Bioengineering, Kansai University, Suita, Osaka 564-8680, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Gold nanorods (AuNRs) possess anisotropic optical and electronic properties, primarily determined by their aspect ratio and surface ligands, which make them attractive for applications in sensing, catalysis, and nanomedicine. While these nanorods are typically stabilized using cetyltrimethylammonium bromide (CTAB) to ensure colloidal dispersion, the cytotoxicity and strong surface affinity of CTAB hinder further surface modification through ligand exchange. In this study, we employed matrix-free laser desorption/ionization time-of-flight mass spectrometry (LDI-TOF-MS) to directly monitor the ligand exchange process on AuNRs. This technique enables the detection of intact CTAB, transient intermediates, and final thiol-bound ligands without requiring chemical derivatization. By correlating mass spectral data with ultraviolet-visible-near-infrared absorption and zeta potential measurements, we elucidate a stepwise ligand exchange mechanism in which CTAB is gradually displaced by a thiol-functionalized phosphorylcholine ligand, facilitated by electrostatic interaction with poly(styrene sulfonate). These findings highlight the utility of matrix-free LDI-TOF-MS as a powerful analytical tool for gaining mechanistic insights into ligand exchange reactions at the nanoscale, particularly in aqueous environments.

Indexed as

CTABgold nanorodsLDI-TOF-MSligand exchangethiolated phosphorylcholine

Identifiers

PMID41438249
PMCPMC12719553

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.